KB Home
KBH
Meritage Homes
MTH
D.R. Horton
DHI
4
Strategy
MSTR
5
Lennar Corp
LEN
US Stock MarketDetailed Quotes
MTNB Matinas BioPharma
- 0.6400
- -0.0040-0.62%
Trading Apr 30 11:19 ET
3.26MMarket Cap-0.13P/E (TTM)
0.6435High0.6218Low800Volume0.6435Open0.6440Pre Close508.08Turnover0.02%Turnover RatioLossP/E (Static)5.09MShares9.600052wk High0.43P/B3.02MFloat Cap0.474852wk Low--Dividend TTM4.71MShs Float197.5000Historical High--Div YieldTTM3.37%Amplitude0.4748Historical Low0.6350Avg Price1Lot Size
Matinas BioPharma Key Stats
EPS
According to the latest financial report of Matinas BioPharma, the latest earnings per share (TTM) for the company is -1.68. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Matinas BioPharma's free cash flow? The latest report shows it as -3.51M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Matinas BioPharma shows that the company's current ratio is 3.01, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Matinas BioPharma, the quick ratio is 2.73, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Matinas BioPharma? The latest ROE figure is -72.17%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Matinas BioPharma, the total asset return on investment (ROA) is -50.77%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Matinas BioPharma's latest financial report to see how their gross margin is doing - currently at --.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Matinas BioPharma, the net profit margin is -503.01%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025